Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Proposal of a Special Issue On: Basic, Translational and Clinical Research on Dementia"
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".
Deadline for manuscript submissions: 31 August 2023 | Viewed by 190
Special Issue Editors
Interests: pharmacology; neurotherapeutics; brain ischemia; glaucoma; pain; herbal medicines
Interests: neurodegenerative disorders; aging; epigenetics; mitochondrial function; metabolism
Interests: basic, translational and clinical research of neurotherapeutics for dementia and pain
Special Issue Information
The global impact of dementia is increasingly worrisome and up to 90% of dementia patients in low- and middle-income countries is not diagnosed with further delays in diagnosis due to the pandemic during which these fragile population pays the highest price.
Alzheimer’s disease (AD) is the most common accounting for about two-thirds of all cases, but mixed forms of dementia are being increasingly recognized, making dementia a public health priority. These different forms may at least in part be explained through progressive alterations of the epigenome that may contribute to the decrease of cognitive abilities with advancing age.
Indeed, there is little doubt that AD is a multifactorial disease, which involves diverse pathogenic mechanisms and will probably require combinatorial therapies. Although many pathological factors, such as accumulation of protein aggregates of amyloid-beta (Aβ) and tau, have been identified, their role in combination with other factors, at different disease stages, requires further clarification. A comprehensive understanding of the complex disease mechanisms, the identification of early disease markers aided by ultrastructural magnetic resonance imaging are necessary to develop more effective treatments.
Although multiple failures of phase III trials with agents targeting Aβ had initially been disappointing, the accelerated approval of mAbs has recently renewed the interest in targeting Aβ. The gain of information from the real-world data on these neurotherapeutics may anticipate that further development of clinical trials in AD will be prompted.
Accordingly, we would like to invite contributions from basic, translational and clinical research on dementia in the form of original, narrative or systematic reviews on each of the above-named topics.
Prof. Dr. Giacinto Bagetta
Dr. Daniele Bano
Dr. Damiana Scuteri
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Alzheimer’s disease
- tau protein